-
公开(公告)号：US20200087395A1
公开(公告)日：2020-03-19
申请号：US16567256
申请日：2019-09-11
发明人： Stephen J Demarest , Anja Koester , Scott Charles Potter , Diana Isabel Ruiz , Derrick Ryan Witcher , Xiufeng Wu , Payal Mehta
摘要： The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
-
公开(公告)号：US20170362315A1
公开(公告)日：2017-12-21
申请号：US15695338
申请日：2017-09-05
IPC分类号： C07K16/24 , A61K39/395 , C07K16/32 , A61K39/00
CPC分类号： C07K16/24 , A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K16/244 , C07K16/32 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
-
公开(公告)号：US20160289342A1
公开(公告)日：2016-10-06
申请号：US15079184
申请日：2016-03-24
CPC分类号： C07K16/468 , A61K2039/505 , C07K16/241 , C07K16/2887 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sjögren's Syndrome.
摘要翻译： 提供结合CD20和B细胞活化因子（BAFF）的双特异性抗体，其特征在于对CD20和BAFF具有高亲和力和强同时中和性质。 本发明的双特异性抗体可用于治疗自身免疫性疾病，包括系统性红斑狼疮，狼疮性肾炎和原发性Siegren综合征。
-
公开(公告)号：US20140271647A1
公开(公告)日：2014-09-18
申请号：US14204089
申请日：2014-03-11
CPC分类号： C07K16/24 , A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K16/244 , C07K16/32 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
摘要翻译： 提供了特异性结合七种人类ELR + CXC趋化因子的抗体。 本发明的抗体可用于治疗各种炎性/自身免疫性疾病，例如炎性肠病（IBD），斑块性银屑病和掌跖脓疱病; 和癌症，如肾癌或卵巢癌。
-
公开(公告)号：US08765129B2
公开(公告)日：2014-07-01
申请号：US13708059
申请日：2012-12-07
IPC分类号： A61K39/395
CPC分类号： C07K16/26 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject.
摘要翻译： 提供选择性结合人hepcidin-25的单克隆抗体，其特征在于具有对人hepcidin-25的高亲和力和强的人成熟铁调素中和特性。 本发明的抗体治疗性地用于增加人的血清铁水平，网织红细胞计数，红细胞计数，血红蛋白和/或血细胞比容，以及用于治疗和诊断人中成熟的铁调素促进的疾病如贫血 学科。
-
公开(公告)号：US20130164304A1
公开(公告)日：2013-06-27
申请号：US13708059
申请日：2012-12-07
CPC分类号： C07K16/26 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject.
-
公开(公告)号：US12037387B2
公开(公告)日：2024-07-16
申请号：US17284611
申请日：2019-10-15
CPC分类号： C07K16/24 , A61K9/0019 , A61P17/00 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Provided herein are methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa. Also provided are doses and dosing regimens for the methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa.
-
公开(公告)号：US20180362631A1
公开(公告)日：2018-12-20
申请号：US16119648
申请日：2018-08-31
IPC分类号： C07K16/24 , C07K16/32 , A61K39/395 , A61K39/00
摘要： Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
-
公开(公告)号：US09290570B2
公开(公告)日：2016-03-22
申请号：US14204089
申请日：2014-03-11
CPC分类号： C07K16/24 , A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K16/244 , C07K16/32 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要： Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
摘要翻译： 提供了特异性结合七种人类ELR + CXC趋化因子的抗体。 本发明的抗体可用于治疗各种炎性/自身免疫性疾病，例如炎性肠病（IBD），斑块性银屑病和掌跖脓疱病; 和癌症，如肾癌或卵巢癌。
-
公开(公告)号：US20140255406A1
公开(公告)日：2014-09-11
申请号：US14195885
申请日：2014-03-04
发明人： Barrett Allan , Andrew Lawrence Glasebrook , Jirong Lu , Ying Tang , Derrick Ryan Witcher , Donmienne Doen Mun Leung , Pia Pauliina Yachi , Andrew Charles Vendel
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/241 , C07K2317/31 , C07K2317/622 , C07K2317/76
摘要： Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNFα) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
摘要翻译： 提供特异性结合肿瘤坏死因子α（TNFα）和白细胞介素-17（IL-17）的双特异性抗体。 本发明的双特异性抗体可用于治疗各种自身免疫疾病，包括类风湿关节炎（RA），银屑病关节炎（PsA）和强直性脊柱炎（AS）。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.019 秒)
